Can-Fite BioPharma Ltd. (CANF)
Stock analysis · AMEX · Healthcare · Biotechnology
Can-Fite BioPharma Ltd. (CANF) is a publicly traded company in the Healthcare sector. Trailing PE -0.26. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for variou…
Valuation
| P/E (TTM) | -0.26× |
|---|---|
| P/S (TTM) | 9.63× |
| P/B | 0.70× |
| PEG | 0.00× |
| P/FCF (TTM) | -0.41× |
| EV / EBITDA | -0.10× |
| EV / Sales | 2.39× |
| Earnings Yield | -282.69% |
| Free Cash Flow Yield | -243.80% |
Fundamentals
| Enterprise Value | $966.04K |
|---|---|
| Revenue (TTM) | $405.00K |
| Net Income (TTM) | -$11.03M |
| Free Cash Flow (TTM) | -$9.51M |
| Net Debt | -$2.94M |
| Working Capital | $5.78M |
| Gross Margin | 100.00% |
| Operating Margin | -2402.96% |
| Net Margin | -2358.77% |
| Return on Equity | -182.89% |
| Return on Invested Capital | -165.57% |
Peers
Recent News
- Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
- Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
- Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing P…
- Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Related
Browse more tickers: sitemap